NGHIÊN CỨU ĐẶC ĐIỂM LÂM SÀNG, CẬN LÂM SÀNG VÀ KẾT QUẢ ĐIỀU TRỊ BẰNG DAPAGLIFLOZIN Ở BỆNH NHÂN SUY TIM PHÂN SUẤT TỐNG MÁU GIẢM KHÔNG ĐÁI THÁO ĐƯỜNG

Abstract

Background: Heart failure is a common cardiovascular disease that causes serious consequences and burdens medical care. Treatment of failure has recently had many new updates with the appearance of Dapagliflozin added to the regimen, leading to changes in clinical practice in Vietnam. Objectives: To describe clinical and paraclinical characteristics and evaluate the results of treatment with Dapagliflozin in patients with heart failure with reduced ejection fraction without diabetes. Materials and methods: Randomized study of 102 patients with heart failure with reduced ejection fraction without diabetes admitted and treated at Can Tho University of Medicine and Pharmacy Hospital and Can Tho Central General Hospital. Results: The average age of the patients was 66.9 ± 13.5 years, men accounted for 57.8%. Dyspnea was the most common symptom (75.5%), and NYHA class III was the most common (60.8%). The mean ejection fraction was 32 ± 6.15%. The median NT-proBNP concentration was 8749 pg/mL. The rate of readmission for heart failure after a 12-week follow-up period in the group of patients treated with Dapagliflozin (9.1%) was lower than in the group not treated with Dapagliflozin (23.4%), the difference was statistically significant ( p = 0.048). Conclusion: Dyspnea is the most common symptom and NYHA class III is the most common in patients with heart failure with reduced ejection fraction without diabetes. The rate of rehospitalization for heart failure after 12 weeks in the Dapagliflozin treatment group was lower than the non-treatment group, the difference was statistically significant.